Maxinject

Cefepime, the active ingredient in Maxinject, is a fourth-generation cephalosporin presented as an injectable solution for intravenous use. It treats severe bacterial infections, including nosocomial pneumonia, febrile neutropenia, urinary tract infections, and skin and soft tissue infections in hospitalized patients.

GNH USA supplies Maxinject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Cefepime is a broad‑spectrum fourth‑generation cephalosporin used to treat infections caused by Gram‑negative and Gram‑positive bacteria.

- Severe bacterial infections: Provides extensive coverage for critically ill patients with systemic infections. - Nosocomial pneumonia: Effective against hospital‑acquired lung infections resistant to earlier‑generation agents. - Febrile neutropenia: Used empirically in immunocompromised patients with fever and low neutrophil counts. - Urinary tract infections: Treats complicated UTIs caused by resistant organisms. - Skin and soft tissue infections: Addresses serious cellulitis and wound infections.

Cefepime may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea: Mild to moderate gastrointestinal upset. - Diarrhea: May be watery and self‑limiting. - Rash: Non‑specific skin eruption. - Infusion site phlebitis: Local irritation at the IV site.

Serious or Rare Side Effects: - Anaphylaxis: Severe, potentially life‑threatening allergic reaction. - Clostridioides difficile colitis: Overgrowth leading to severe diarrhea. - Seizures: Particularly in patients with renal impairment or high plasma concentrations.

When using Maxinject, clinicians should consider several precautionary measures to ensure safe therapy.

- Renal function: Adjust dosage in patients with impaired renal clearance. - Hypersensitivity: Discontinue immediately if signs of allergic reaction appear. - Seizure risk: Monitor patients with pre‑existing central nervous system disorders. - Clostridioides difficile infection: Be aware of potential overgrowth during or after therapy. - Store at 2‑8°C: Keep refrigerated, protect from light, do not freeze.

Cefepime can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., aminoglycosides): May increase risk of renal injury. - Probenecid: Can raise cefepime plasma concentrations. - Other β‑lactam antibiotics: May lead to additive toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: May affect electrolyte balance. - Anticoagulants: Potential alteration of INR values. - Live vaccines: May reduce vaccine efficacy.